Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Dec 05, 2022 11:23am
Repeated Violations of Stockhouse's Content Rules
Dumpster, I really suggest you familiarize yourself with Stockhouse's new content rules. You have already had three posts removed since November 28th for violations of the rules. This
...more
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Dec 01, 2022 5:29pm
The other two goons??
Oh you mean Mugsy and Pez!! Goon is a little harsh i think.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Dec 01, 2022 4:52pm
RE:RE:RE:RE:To do list ... IMO
Hahaha - interesting. This is a very good place for some to really think about what this investment is ... In drug development, there is a lot of development work done in secrecy - it has to be that
...more
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Dec 01, 2022 1:27pm
RE:RE:RE:RE:To do list ... IMO
not surprised you were not looking for honest answer
(48)
•••
WalterWheat21
X
View Profile
View Bullboard History
Comment by
WalterWheat21
on Dec 01, 2022 12:15pm
RE:RE:RE:To do list ... IMO
Please don't respond back to me. You are the lowest *** and no one here wants to hear from you, or the other 2 goons.
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Dec 01, 2022 10:07am
RE:RE:RE:Stockhouse Bullboard Content Management Changes
How to avoid labelled as misinformation. Say IMO after
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Dec 01, 2022 10:00am
Nice volume tod
This stock is garnishing some real interest.......
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Dec 01, 2022 8:55am
RE:RE:Stockhouse Bullboard Content Management Changes
This site is designed for debate around potential misinformation Duster. Just stay focused on ATE. ------------------- Note: Today is Dec 1. Indomethacin/Ketotifen P3 COVID trial is due to
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Dec 01, 2022 1:51am
RE:Stockhouse Bullboard Content Management Changes
i guess free speach is not allowed, you guys better hope elon musk does not buy S.H. lol, otherwise it will turn into a cesspool like twiter was. missinformation is ok though cause i read alot
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 30, 2022 5:42pm
RE:RE:To do list ... IMO
I don't think we will get any additional information on the IP. If I understand ... they now have one year to fortify their position with that IP ... to make it stronger. Likely tight lipped
...more
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Nov 30, 2022 4:31pm
Stockhouse Bullboard Content Management Changes
It is refreshing to see that Stockhouse has followed through on its commitment to improve content on the bullboards. I noticed that one of our loyal trolls (you know who he is) posted his
...more
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Nov 30, 2022 12:16pm
RE:RE:To do list ... IMO
average time 2 or 3 years
(48)
•••
WalterWheat21
X
View Profile
View Bullboard History
Comment by
WalterWheat21
on Nov 30, 2022 10:05am
RE:To do list ... IMO
How soon do you think we'll hear about the patent approval for the amorphous formulation?
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Nov 28, 2022 2:17pm
To do list ... IMO
To Do List (2022 and 2023) ... 1. IBD update (before Christmas 2022) 2. Animal Studies (late 2022 or early 2023) - assume little is shared here 3. IND studies begin for IBD - 2023 4
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Nov 27, 2022 11:44pm
presentation updated
Presentation update ... Page 9 - 3rd party commercial validation Page 16 - NSAID of choice ... protection to 2043 Page 17 - Development plan Page 26 - Insider ownership at 15%
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >